These results suggest that distinct molecular mechanisms, specifically those affecting the sensitivity to different drugs, may be responsible for the miR-21-mediated resistance to trastuzumab and chemotherapy in HER2-positive cancer cells. Here, ERBB2 is linked to cancer.